Affimed - AFMD Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AFMD shares.
View AFMD analyst ratings or view top-rated stocks.

7 Wall Street analysts have issued 1 year target prices for Affimed's stock. Their AFMD share price forecasts range from $7.00 to $12.00. On average, they expect the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 402.5% from the stock's current price.
View analysts price targets for AFMD or view top-rated stocks among Wall Street analysts.

Affimed's stock was trading at $5.52 on January 1st, 2022. Since then, AFMD stock has decreased by 63.9% and is now trading at $1.99.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our AFMD earnings forecast.

Affimed (NASDAQ:AFMD) released its earnings results on Thursday, August, 11th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.04. The biopharmaceutical company earned $7.78 million during the quarter, compared to analyst estimates of $8.12 million. Affimed had a negative trailing twelve-month return on equity of 54.94% and a negative net margin of 232.11%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Affimed investors own include Novavax (NVAX), JetBlue Airways (JBLU), SentinelOne (S), American International Group (AIG), Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Amarin (AMRN), Rigel Pharmaceuticals (RIGL), Viking Therapeutics (VKTX) and Lipocine (LPCN).

Affimed trades on the NASDAQ under the ticker symbol "AFMD."

Affimed's stock is owned by a number of retail and institutional investors. Top institutional investors include Point72 Asset Management L.P. (5.23%), Pictet Asset Management SA (3.88%), Woodline Partners LP (2.03%), State Street Corp (1.82%), Bain Capital Public Equity Management II LLC (1.03%) and Northern Trust Corp (0.80%).

Shares of AFMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AFMD stock can currently be purchased for approximately $1.99.

Affimed (NASDAQ:AFMD) has a market capitalization of $245.61 million and generates $47.76 million in revenue each year. The biopharmaceutical company earns $-68,060,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis.

The company employs 197 workers across the globe.

Affimed's mailing address is TECHNOLOGIEPARK IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The official website for the company is www.affimed.com. The biopharmaceutical company can be reached via phone at 496221674360, via email at ir@affimed.com, or via fax at 49-6221-653-0777.